Nxera Pharma's NBI-1117568, Backed by Neurocrine Biosciences, Successfully Completes Long-Term Preclinical Toxicity Program
Portfolio Pulse from Benzinga Newsdesk
Nxera Pharma's NBI-1117568, an oral, selective muscarinic M4 receptor agonist, has successfully completed a long-term preclinical toxicity program. This achievement, part of a collaboration with Neurocrine Biosciences, triggers a $15 million payment to Nxera from Neurocrine. NBI-1117568 is advancing through Phase 2 clinical development.
April 16, 2024 | 7:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences, collaborating with Nxera Pharma on NBI-1117568, has made a $15 million payment following the successful completion of a preclinical toxicity program.
The successful completion of the preclinical toxicity program for NBI-1117568 not only marks a significant milestone in the drug's development but also strengthens the collaboration between Neurocrine Biosciences and Nxera Pharma. This progress could positively influence investor sentiment towards Neurocrine Biosciences, as it demonstrates advancement in their pipeline and effective use of their capital towards promising treatments. The payment signifies commitment and progress in their partnership, potentially leading to positive market reactions.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90